Earlier this month when the MRD team gathered for our national meeting, Adapter Yvette Rodriguez led a bone marrow registry drive in partnership with There Goes My Hero. We’re proud of our Adapters who signed up to be a potential match for a patient in need. #MultipleMyelomaAwarenessMonth

In myeloma, access to MRD testing is critical for informing a personalized care management approach. #MyelomaAwarenessMonth

The analysis of MRD took center stage at ASH 2023. Check out our digest of the MRD data highlights across MM, NHL and CLL. adaptivebio.tech/2g6

Today, FDA’s ODAC voted unanimously in favor of the use of MRD as an endpoint to support accelerated approval of new therapies for patients with multiple myeloma. This is fantastic news with the potential to bring life-saving therapies to patients sooner. bit.ly/3Q4VVdJ

Happy Medical Laboratory Professionals Week! This week we honor the remarkable clinical lab staff, scientists and all those who contribute to the seamless functioning of our laboratories. You play a crucial role in the care of our patients. Thank you. #LabWeek2024

This #EarthDay2024, our Sustainability @ Adaptive ERG is tending our rooftop garden, from which crops are donated to local food banks or used as snacks. Honoring this year’s theme, ‘Plastics vs. Planet,’ the team is also conducting a plastics audit to assess our impact.

In celebration of #LabWeek2024, we hosted a number of events for our clinical and R&D lab professionals across our sites. We want to express our gratitude to all of our colleagues in the lab for their role in improving the lives of our patients. We hope you had a great week!

For MM teams looking to incorporate clonoSEQ MRD testing, check out the easy-to-use NCODA guide adaptivebio.tech/upn FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: rb.gy/8tju9y

clonoSEQ® MRD assessment data to be presented at #ASCO24 and #EHA2024 across blood cancers. adaptivebio.tech/v4l FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: rb.gy/8tju9y

Ben Derman, MD presents strategies to discontinue maintenance therapy based on MRD negativity status in #MultipleMyeloma pts. This approach not only improves quality of life but saves a lot of money. #ASCO24 Ben Derman UChicagoCancerCenter University of Chicago Hematology/Oncology

Three new Adaptive manuscripts shed light on the complex relationship between T-cell responses and various exposures, offering new avenues for research and clinical applications. Learn more: adaptivebio.tech/5zm

Adapters are gearing up for Obliteride 2024 through a packed schedule of team training rides! We're proud to support Fred Hutchinson Cancer Center to #CureCancerFaster.

Led by our Black Adapter Network, this Juneteenth we celebrate the resilience and joy of the African American community. Today serves as an important reminder that the struggle for freedom, equality, and justice is ongoing.

Adaptive is eager to explore how MRD testing can add insight to the clinical assessment of MGUS and SMM patients. Together with Foundation for the National Institutes of Health we aim to transform patient care and improve quality of life. Learn more at fnih.org/MMyeRisk.

At Adaptive, we are committed to fostering a powerful sense of community and belonging. Read about our Pride Month celebrations: adaptivebio.tech/4fi

On June 30, Adaptive employees braved the threat of rain to join the Seattle community in the Defeat Multiple Myeloma Run/Walk. It was an incredible event and great opportunity to raise funds for immunotherapy research at the Fred Hutch Cancer Research Center.

Congratulations Schwab Lab on the publication of their study in Brain. Adaptive immunosequencing enabled the quantification of EBV-specific TCRBs in these patients, providing new insight into the role of EBV in triggering and driving multiple sclerosis.

Susan Bobulsky, chief commercial officer, MRD at Adaptive was interviewed by Inside Precision Medicine discussing the benefit of MRD testing using clonoSEQ and how it can change the existing treatment paradigm for certain blood cancers. Read more: adaptivebio.tech/mf6

Adaptive announces clonoSEQ IVDR certification, the first CE-marked MRD test to meet this standard. adaptivebio.tech/kmh FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: rb.gy/8tju9y

At this year's ASCO and EHA meetings, a multitude of clinical trial data and real-world evidence underscored the clinical benefit of specific and sensitive MRD assessment. Read our summary: adaptivebio.tech/3wj